In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protalix BioTherapeutics Inc.

www.protalix.com

Latest From Protalix BioTherapeutics Inc.

Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.

Approvals Rare Diseases

Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal

LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.

Deals M & A

More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.

Rare Diseases Health Technology Assessment

Chiesi Committed To Becoming A Major Player In Rare Diseases

The Italian group has got the green light in Europe for Lamzede, the first disease-modifying therapy for alpha mannosidosis and believes the drug, along with Procysbi and an investigational Fabry disease being developed with Protalix, constitute a strong portfolio in the rare metabolic disease area.

Rare Diseases Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Protalix BioTherapeutics Ltd.
  • Metabogal Ltd.
  • Orthodontix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Protalix BioTherapeutics Inc.
  • Senior Management
  • Dror Bashan, Pres. & CEO
    Eyal Rubin, SVP, CFO
    Yoseph Shaaltiel, PhD, EVP, R&D
    Ronen Rosenberg, VP, Commercial & Product Planning
    William Taylor, VP, Bus. Dev.
  • Contact Info
  • Protalix BioTherapeutics Inc.
    Phone: (972) 4-902-8100
    2 Snunit St., Science Park
    P.O. Box 455 Karmiel, 21000
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register